miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling

References

• Wu J, Sun H, Li J, et al. Increased survival of patients aged 0-29 years with osteosarcoma: a period analysis, 1984-2013. Cancer Med. 2018;7(8):3652–3661.
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532.
   PubMed Web of Science ®Google Scholar
• Vishnubalaji R, Hamam R, Abdulla MH, et al. Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer. Cell Death Dis. 2015;6(1):e1614.
   PubMedGoogle Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–5465.
   PubMed Web of Science ®Google Scholar
• Berlanga P, Munoz L, Piqueras M, et al. miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis. Mol Oncol. 2016;10(7):1043–1053.
   PubMed Web of Science ®Google Scholar
• Sampson VB, Yoo S, Kumar A, et al. MicroRNAs and potential targets in osteosarcoma: review. Front Pediatr. 2015;3:69.
   PubMed Web of Science ®Google Scholar
• Lu J, Song G, Tang Q, et al. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene. 2017;36(2):231–241.
   PubMed Web of Science ®Google Scholar
• Jaszai J, Schmidt MHH. Trends and challenges in tumor anti-angiogenic therapies. Cells. 2019;8(9):1102.
   PubMed Web of Science ®Google Scholar
• Quan GM, Choong PF. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev. 2006;25(4):707–713.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishikawa T, Iwai S, et al. Fibroblast growth factor-2 is an important factor that maintains cellular immaturity and contributes to aggressiveness of osteosarcoma. Mol Cancer Res. 2012;10(3):454–468.
   PubMed Web of Science ®Google Scholar
• Allen-Rhoades W, Kurenbekova L, Satterfield L, et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015;4(7):977–988.
   PubMed Web of Science ®Google Scholar
• Tang Q, Lu J, Zou C, et al. CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis. Oncogene. 2018;37(27):3617–3630.
   PubMed Web of Science ®Google Scholar
• Gentile MT, Pastorino O, Bifulco M, et al. HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis. J Vis Exp. 2019;148: DOI: 10.3791/58591.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Pan L, Yang H, Tang W, et al. Pathway-focused PCR array profiling of CAL-27 cell with over-expressed ZNF750. Oncotarget. 2018;9(1):566–575.
   PubMedGoogle Scholar
• Ming J, He PY, Liu J, et al. MicroRNA-17-5p regulates the growth, migration and invasion of the human osteosarcoma cells by modulating the expression of PTEN. J BUON. 2020;25:1028–1034.
   PubMed Web of Science ®Google Scholar
• Yang J, Ma Z, Wang Y, et al. Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein. Exp Ther Med. 2018;15:461–466.
   PubMed Web of Science ®Google Scholar
• Liang C, Zhou A, Sui C, et al. The effect of formononetin on the proliferation and migration of human umbilical vein endothelial cells and its mechanism. Biomed Pharmacother. 2019;111:86–90.
   PubMed Web of Science ®Google Scholar
• Cheng DD, Li SJ, Zhu B, et al. Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway. Oncol Rep. 2017;38(4):2116–2122.
   PubMed Web of Science ®Google Scholar
• Lukin DJ, Carvajal LA, Liu WJ, et al. p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Mol Cancer Res. 2015;13(1):16–28.
   PubMed Web of Science ®Google Scholar
• Cao R, Shao J, Hu Y, et al. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018;18(1):49.
   PubMedGoogle Scholar
• Li S, Zhu Y, Liang Z, et al. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer. Oncotarget. 2016;7(32):51773–51783.
   PubMedGoogle Scholar
• Wang C, Gu S, Cao H, et al. , miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis. Sci Rep. 2016;6(1):30122.
   PubMedGoogle Scholar
• Xu W, Hu GQ, Da Costa C, et al. Long noncoding RNA UBE2R2-AS1 promotes glioma cell apoptosis via targeting the miR-877-3p/TLR4 axis. Onco Targets Ther. 2019;12:3467–3480.
   PubMed Web of Science ®Google Scholar
• Ren MH, Chen S, Wang LG, et al. LINC00941 Promotes Progression of Non-Small Cell Lung Cancer by Sponging miR-877-3p to Regulate VEGFA Expression. Front Oncol. 2021;11:650037.
   PubMed Web of Science ®Google Scholar
• Chen S, Li K. HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer. BMC Cancer. 2020;20(1):924.
   PubMed Web of Science ®Google Scholar
• Wang Z, Song K, Zhao W, et al. Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. Bioengineered. 2020;11(1):661–678.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–516.
   PubMed Web of Science ®Google Scholar
• Sun B, Liu Y, Huang W, et al. Functional identification of a rare vascular endothelial growth factor a (VEGFA) variant associating with the nonsyndromic cleft lip with/without cleft palate. Bioengineered. 2021;12(1):1471–1483.
   PubMed Web of Science ®Google Scholar
• Lu J, Wang YH, Yoon C, et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2020;471:38–48.
   PubMed Web of Science ®Google Scholar
• Zhang D, Lv FL, Wang GH. Effects of HIF-1alpha on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci. 2018;22:5071–5076.
   PubMed Web of Science ®Google Scholar
• Zhou G, Xie J, Gao Z, et al. MicroRNA-877 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting IGF-1R. Exp Ther Med. 2019;18:1449–1457.
   PubMed Web of Science ®Google Scholar
• He G, Chen J, Huang D. miR-877-3p promotes TGF-beta1-induced osteoblast differentiation of MC3T3-E1 cells by targeting Smad7. Exp Ther Med. 2019;18:312–319.
   PubMed Web of Science ®Google Scholar
• Dianat-Moghadam H, Teimoori-Toolabi L. Implications of Fibroblast Growth Factors (FGFs) in Cancer: from Prognostic to Therapeutic Applications. Curr Drug Targets. 2019;20(8):852–870.
   PubMed Web of Science ®Google Scholar
• Ronca R, Giacomini A, Rusnati M, et al. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets. 2015;19(10):1361–1377.
   PubMed Web of Science ®Google Scholar